1Rao AR,Motiwala HG,Karim OM.The discovery of prostate specific antigen[J].BJU Int,2008,101(1):5-10.
2Polascik TJ,Oesterling JE,Partin AW.Prostate specific antigen:a decade of discovery-What we have learned and where we are going[J].J Urol,1999,162(2):293-303.
3S(o)létormos G,Semjonow A,Sibley PE,et al.Biological variation of total prostatespecific antigen:a survey of published estimates and consequences for clinical practice[J].Clin Chem,2005,51(8):1342-1351.
4De Angelis G,Rittenhouse HG,Mikolajczyk BA,et al.Twenty years of PSA:from prostate antigen to tumor marker[J].Rev Urol,2007,9(3):113-123.
5Sirovich BE,Schwartz LM,Woloshin S.Screening men for prostate and colorectal cancer in the United States:does practice reflect the evidence?[J].JAMA,2003,289(11):1414-1420.
6Labrie F,Dupont A,Suburu R,et al.Serum prostate specific antigen as preprescreening test for prostate cancer[J].J Urol,1992,147(3 Pt 2):846-851.
7Thompson IM,Pauler DK,Goodman PJ,et al.Prevalence of prostate cancer among men with a prostate-specific antigen level 《 or =4.0 ng per millilitre[J].N Engl J Med,2004,350(22):2239-2246.
8Yu X,Han M,Loeb S,et al.Comparison of methods for calculating prostate specific antigen velocity[J].J Urol,2006,176(6 Pt 1):2427-2431.
9Moul JW,Sun L,Hotaling JM,et al.Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening[J].J Urol,2007,177(2):499-503.
10Thompson IM,Ankerst DP,Chi C,et al.Assessing prostate cancer risk:results from the Prostate Cancer Prevention Trial[J].J Natl Cancer Inst,2006,98(8):529-534.
